News and Views
Nature Medicine 13, 1018 - 1019 (2007)
doi:10.1038/nm0907-1018
Schizophrenia drug says goodbye to dopamine
Daniel R Weinberger1
- Daniel R. Weinberger is at the Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA. e-mail: daniel.weinberger@mail.nih.gov
Abstract
A drug that activates glutamate receptors offers promise for a new class of anti-psychotic therapeutics and sheds light on the pathophysiology of this devastating disease (pages 1102–1107).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
An emerging pathophysiologyNature News and Views (13 Feb 1997)
Neuroscience A complex in psychosisNature News and Views (06 Mar 2008)
RESEARCH
Stimulation of α2-Adrenoceptors Suppresses Excitatory Synaptic Transmission in the Medial Prefrontal Cortex of RatNeuropsychopharmacology Original Article
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine Letter (01 Sep 2007)
See all 45 matches for Research
